Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 21, 2024
Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year
Arash Mostaghimi, Matthias Augustin, Kazutoshi Harada, et al.
The American Journal of Gastroenterology
|
March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
Scott D Lee, Severine Vermeire, Ryan Ungaro, et al.
Journal of the American Academy of Dermatology
|
November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.
Dermatology and Therapy
|
June 21, 2024
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, et al.
Dermatology and Therapy
|
October 15, 2024
Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, et al.
Journal of the American Academy of Dermatology
|
June 6, 2021
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Brett King, Justin Ko, Seth Forman, et al.
JAMA Dermatology
|
August 14, 2024
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial
Brett King, Justin Ko, Ohsang Kwon, et al.
Journal of the American Academy of Dermatology
|
October 24, 2024
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2
Brett King, Manabu Ohyama, Maryanne Senna, et al.
American Journal of Clinical Dermatology
|
March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.
Journal of the American Academy of Dermatology
|
June 9, 2024
Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
Arash Mostaghimi, Justin Ko, Antonella Tosti, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Journal of the European Academy of Dermatology and Venereology : JEADV
|
November 21, 2024
Continued treatment with baricitinib results in meaningful scalp responses among scalp non-responder patients with eyebrow/eyelash regrowth in the first year
Arash Mostaghimi, Matthias Augustin, Kazutoshi Harada, et al.
The American Journal of Gastroenterology
|
March 13, 2025
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
Scott D Lee, Severine Vermeire, Ryan Ungaro, et al.
Journal of the American Academy of Dermatology
|
November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.
Dermatology and Therapy
|
June 21, 2024
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, et al.
Dermatology and Therapy
|
October 15, 2024
Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Brittany Craiglow, Yang Won Lee, Sergio Vañó-Galván, et al.
Journal of the American Academy of Dermatology
|
June 6, 2021
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Brett King, Justin Ko, Seth Forman, et al.
JAMA Dermatology
|
August 14, 2024
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial
Brett King, Justin Ko, Ohsang Kwon, et al.
Journal of the American Academy of Dermatology
|
October 24, 2024
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2
Brett King, Manabu Ohyama, Maryanne Senna, et al.
American Journal of Clinical Dermatology
|
March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.
Journal of the American Academy of Dermatology
|
June 9, 2024
Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
Arash Mostaghimi, Justin Ko, Antonella Tosti, et al.
Page
of 4